Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Marsh & McLennan reports third-quarter earnings on October 15 with the stock at $177.01, up 3.1% on the week and sitting above both the cautious analysts' targets and the level at which two previous notes found it drifting.
The gains since the October 12 earnings preview are worth noting, but the structural picture those notes described has not changed. The analyst camp remains split between holders who have trimmed and those who have lifted. Wells Fargo's Elyse Greenspan cut her target on October 12 to $183 from $188, maintaining Equal-Weight, the most recent move and one that puts her floor below the current price. Morgan Stanley and Mizuho also trimmed in the days prior, each keeping neutral ratings. The other side holds firm: UBS raised to $222 last week and JPMorgan lifted to $215 on October 1, both reiterating positive ratings. The consensus mean of $202.67 implies roughly 14% upside from current levels, but with the stock now trading above $183 to $190, the cautious analysts' targets are already in the rearview mirror. That narrows the range of scenarios where they would feel compelled to act on the upside, while leaving the bulls with plenty of room.
The lending market is not part of the story. Availability is extraordinarily loose, with more than 328 million shares available to borrow against roughly 6.2 million sold short. Short interest at 1.3% of the free float is minimal, up just under 4% on the week but well below where it was a month ago. Cost to borrow is 0.41%, barely above zero. There is no short-side pressure and no squeeze dynamic. Options are similarly unexcited: the put/call ratio of 0.88 is only marginally above its 20-day average of 0.86, with a z-score of 0.38. Neither options traders nor short sellers are positioning for a dramatic move.
The insider record adds a note of caution that the stock price has not yet priced. SEC filings show CEO John Doyle exercised and sold 16,656 shares on September 2 under a pre-arranged 10b5-1 plan, realising roughly $3.1 million. The Chief Marketing Officer sold 6,500 shares in early August outside any declared plan, and the Chief Client Officer sold 7,100 shares in late July, also without a plan. Net insider activity across the past 90 days amounts to roughly 44,000 shares sold for a net value of negative $8.2 million. The CEO's sale was plan-driven, which reduces its signal value, but the CMO and CCO moves were discretionary. Against the backdrop of a stock that has drifted well below its year-ago levels, that pattern is consistent with what analysts on the cautious side have been signalling.
Earnings history adds one more data point to frame tomorrow. The July 2026 print saw the stock fall 3.4% on the day, then recover 5.5% over the following five days. The pattern suggests the market has historically found a floor after initial post-earnings weakness, though the reaction in July followed a period when the stock was trading higher than it is now.
The print tomorrow is the test of whether the bulls' higher targets or the cautious analysts' lower ones better reflect the underlying earnings trajectory; the stock's recovery this week has already moved it past some of the floor estimates, making the bar for a positive surprise reaction somewhat lower than it appeared earlier in the month.
See the live data behind this article on ORTEX.
Open MRSH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
